Vaxcyte Company Insiders
| PCVX Stock | USD 33.25 0.02 0.06% |
Vaxcyte employs about 414 people. The company is managed by 15 executives with a total tenure of roughly 966 years, averaging almost 64.0 years of service per executive, having 27.6 employees per reported executive. Break down of Vaxcyte's management performance can provide insight into the company performance.
Vaxcyte Management Team Effectiveness
The company has return on total asset (ROA) of (0.1453) % which means that it has lost $0.1453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1966) %, meaning that it created substantial loss on money invested by shareholders. Vaxcyte's management efficiency ratios could be used to measure how well Vaxcyte manages its routine affairs as well as how well it operates its assets and liabilities.Vaxcyte Workforce Comparison
Vaxcyte is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 105,300. Vaxcyte adds roughly 414 in number of employees claiming only tiny portion of equities under Health Care industry.
Vaxcyte Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vaxcyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vaxcyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Vaxcyte insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Brandicourt Olivier over two weeks ago Acquisition by Brandicourt Olivier of 1148 shares of Vaxcyte subject to Rule 16b-3 | ||
Paya Carlos V over three weeks ago Acquisition by Paya Carlos V of 3041 shares of Vaxcyte subject to Rule 16b-3 | ||
Wassil Jim over a month ago Disposition of tradable shares by Wassil Jim of Vaxcyte at 87.94 subject to Rule 16b-3 | ||
Guggenhime Andrew over three months ago Disposition of 4777 shares by Guggenhime Andrew of Vaxcyte at 20.93 subject to Rule 16b-3 | ||
Pickering Grant over three months ago Disposition of 15781 shares by Pickering Grant of Vaxcyte at 5.35 subject to Rule 16b-3 | ||
Pickering Grant over three months ago Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3 | ||
Pickering Grant over three months ago Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3 | ||
Pickering Grant over three months ago Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3 |
Vaxcyte Notable Stakeholders
A Vaxcyte stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Vaxcyte often face trade-offs trying to please all of them. Vaxcyte's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Vaxcyte's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andrew MBA | President CFO | Profile | |
| MS MBA | Executive COO | Profile | |
| Mikhail JD | General VP | Profile | |
| Karen Alderete | Ex HR | Profile | |
| Whitney Jones | Chief Officer | Profile | |
| Ashish MBA | CoFounder Officer | Profile | |
| Jeff Fairman | CoFounder Research | Profile | |
| Mark MBA | Chief Officer | Profile | |
| Grant MBA | CEO CoFounder | Profile | |
| Harp MBA | Chief Officer | Profile | |
| Paul MBA | Senior Manufacturing | Profile | |
| MBA MBA | Sr Manufacturing | Profile | |
| Sam Iki | Senior Management | Profile | |
| Janet Graesser | Senior Relations | Profile | |
| Elvia Cowan | Senior Officer | Profile |
About Vaxcyte Management Performance
The success or failure of an entity such as Vaxcyte often depends on how effective the management is. Vaxcyte management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Vaxcyte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Vaxcyte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. Vaxcyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people.
Please note, the imprecision that can be found in Vaxcyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Vaxcyte. Check Vaxcyte's Beneish M Score to see the likelihood of Vaxcyte's management manipulating its earnings.
Vaxcyte Workforce Analysis
Traditionally, organizations such as Vaxcyte use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Vaxcyte within its industry.Vaxcyte Manpower Efficiency
Return on Vaxcyte Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.1M | |
| Net Loss Per Executive | 30.9M | |
| Working Capital Per Employee | 4M | |
| Working Capital Per Executive | 109.9M |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.